TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) announced a letter of intent with Acumen Diagnostics to license the rights for the sepsis PCR-based diagnostic test AcuSept® in the U.S. This test identifies 19 mRNA biomarkers related to infection and sepsis and can yield results within 5 hours. Sepsis, having dire consequences in hospitals, costs the U.S. healthcare system over $62 billion annually. AcuSept has shown superior sensitivity compared to existing tests, aiding in the early diagnosis of sepsis. Provista Diagnostics will conduct clinical validation studies to support FDA submissions.

On March 27, 2023, Todos Medical (OTCQB: TOMDF) announced its Ordinary shares will commence trading on the OTC Pink marketplace following a decline in closing bid prices below $0.001 for five consecutive days, from March 20 to March 24, 2023. The company specializes in medical diagnostics, particularly in cancer detection through its proprietary Todos Biochemical Infrared Analyses (TBIA). Todos recently acquired Provista Diagnostics to leverage its lab for PCR COVID testing and cancer diagnostics. Additionally, Todos is advancing blood tests for neurodegenerative disorders and has formed a joint venture, 3CL Pharma, for developing protease inhibitor products.

Todos Medical, Ltd. (OTCQB: TOMDF) supports International Long COVID Awareness Day, emphasizing the need for increased awareness and resources for the condition impacting millions globally. CEO Gerald Commissiong highlighted Long COVID as a mass disabling event that should be prioritized in pandemic responses. The company is exploring the potential of its dietary supplement, Tollovid, through a planned prospective study targeting Long COVID. Todos Medical is dedicated to advancing solutions for the Long COVID community and has published research suggesting viral persistence as a key factor in the syndrome.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a 21-day moratorium on the conversion of its convertible notes, effective March 13, 2023. This strategy aims to balance immediate capital needs while preserving the company's OTCQB listing. The moratorium allows time to negotiate a new financing agreement that supports ongoing operations and key transactions. The CEO emphasized the importance of addressing the company's declining share price due to broader market uncertainties. Todos continues to pursue funding for its majority-controlled subsidiary, 3CL Pharma, and seeks to enhance revenue at its diagnostic lab, Provista Diagnostics.

Todos Medical, Ltd. (OTCQB: TOMDF) provided a corporate update highlighting significant developments in diagnostic testing amid a surge in respiratory viruses. The company reported over 30,000 tests billed in February, driven by new lab agreements in New York/New Jersey. Their Long COVID Panel in partnership with Amerimmune Diagnostics is generating valuable biomarker data. Todos plans to launch proprietary tests, targeting substantial markets including breast cancer and Alzheimer's. The company is also preparing a crowdfunding campaign for its subsidiary, 3CL Pharma. Additionally, Todos is pursuing a listing on the NYSE American Exchange.

Todos Medical, Ltd. (OTCQB: TOMDF) has initiated a validation plan for a PCR-based test for Avian Influenza A (H5N1) in humans at its CLIA/CAP-certified lab, Provista Diagnostics. The current H5N1 strain is notably deadly, with a 56% mortality rate in humans. Over 58 million poultry have been affected across the U.S., raising concerns about its potential mutation to more transmissible forms. CEO Gerald E. Commissiong emphasized the importance of their automated testing capabilities in addressing airborne pathogens. Todos Medical specializes in diagnostic solutions for cancer and is also expanding into neurodegenerative disorder detection.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that President & CEO Gerald Commissiong will present at the RHK 2022 Disruptive Growth Conference on December 6 at 12:20 PM ET. The company specializes in medical diagnostics, focusing on early cancer detection and COVID-19 solutions, including the 3CL protease inhibitor immune support dietary supplement, Tollovid. Todos has also developed proprietary cancer screening technologies and acquired Provista Diagnostics for expanded diagnostics. For more information about their products, visit Todos Medical.